Comparison
Semaglutide vs Semax
Side-by-side of Semaglutide and Semax. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Semax
Semax peptide benefits: nootropic ACTH(4-10) analog without corticotropic activity. Cognitive enhancement, neuroprotection, intranasal dosing, Russian stroke.
Effects at a glance
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Semax
- •Synthetic heptapeptide analog of ACTH(4-10) developed in Russia in the 1980s
- •Approved in Russia for ischemic stroke, cognitive impairment, and cerebrovascular disorders
- •Lacks the corticotropic activity of native ACTH due to the Pro-Gly-Pro stabilizing tail
- •Russian RCTs report improved cognitive recovery in acute ischemic stroke versus standard care
- •Modulates BDNF and NGF expression and dopaminergic signaling in preclinical models
- •Standard route is intranasal; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | Semaglutide | Semax |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Ozempic, Wegovy, Rybelsus | Met-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) Pro-Gly-Pro analog |
| Half-life (hr) ↗ | 168 | 0.5 |
| Typical dose (mg) ↗ | 2.4 | 0.6 |
| Dosing frequency | weekly (SC); daily (oral Rybelsus) | 2-3x daily (intranasal) |
| Routes | subcutaneous, oral | intranasal |
| Onset (hr) | 24 | 0.5 |
| Peak (hr) | 72 | 2 |
| Molecular weight | 4113.58 | 813.94 |
| Molecular formula | - | C37H51N9O10S |
| Mechanism | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. | Modulates BDNF and NGF expression in hippocampus and cortex, enhances dopaminergic and serotonergic signaling, and reduces oxidative stress markers in preclinical ischemia models. Lacks corticotropic activity of native ACTH. |
| Legal status | Prescription only (FDA-approved, EMA-approved) | Approved in Russia for stroke and cognitive disorders; not FDA approved; research-use-only grey market elsewhere |
| WADA status | allowed | unknown |
| DEA / Rx | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Not recommended; discontinue 2 months before planned pregnancy | Not recommended; insufficient data |
| CAS | 910463-68-2 | 80714-61-0 |
| PubChem CID | 56843331 | 9811102 |
| Wikidata | Q27089394 | Q4413083 |
Safety profile
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Semax
Common side effects
- mild nasal irritation
- transient mild headache
- rare mild euphoria or activation
Contraindications
- pregnancy
- lactation
- acute psychotic disorder
- severe hypertension (caution due to mild activating effect)
Interactions
- stimulants (caffeine, amphetamines): potential additive activation; monitor for overstimulation(minor)
- antipsychotics: theoretical antagonism via dopaminergic modulation(minor)
Which Should You Take?
Semaglutide comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Semax is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
- → If your priority is focus or working memory, pick Semax.
- → If your priority is long-term neuroprotection, pick Semax.
Edge case: Half-lives differ materially (Semaglutide ~168 hr vs Semax ~0.5 hr). Semaglutide reaches steady state faster; Semax is easier to dial in if tolerability is uncertain.
Default choice: Semaglutide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semax only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Semaglutide and Semax?
Semaglutide and Semax differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Semaglutide or Semax?
Semaglutide half-life is 168 hours; Semax half-life is 0.5 hours.
Can you stack Semaglutide with Semax?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper